Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

NCT03242967 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Revised study design.

Conditions

Anemia
Dialysis-Dependent Chronic Kidney Disease

Interventions

DRUG: Vadadustat
DRUG: Darbepoetin alfa

Sponsor

Akebia Therapeutics